This site is intended for health professionals only
Newsletter
Hospital Healthcare Europe
Login
Twitter
Linkedin
Facebook
Select Language
English
French
German
Italian
Spanish
News
Views
Reviews & Research
Clinical
Cardiovascular
Dermatology
Gastroenterology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Sponsored
Events
News
Views
Reviews & Research
Clinical
Cardiovascular
Dermatology
Gastroenterology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Sponsored
Events
Home
>
Central nervous system
Central nervous system
Treatment with VX-661 and Ivacaftor result in improvements in lung function in CF
GW Pharmaceuticals announces Sativex® rescheduled in the UK
Novartis confirms growing Gilenya® clinical experience
Unmet medical need of multiple sclerosis
Collaboration agreement in cognitive disorders
Ivacaftor: a quantum leap in treating cystic fibrosis?
The future for patients with cystic fibrosis and G551D
Global perspectives and compounding problems
UNITAID – Financed project to increase access to new HIV monitoring technology
European commission approves PREZISTA®
The world’s premier cardiovascular congress goes to Amsterdam
FDA approval of Rebif Rebidose
« Previous
1
…
4
5
6
7
8
…
28
Next »
Most read
1
Oral vitamin A could become an alternative to isotretinoin for acne
by Rod Tucker
2
Transcranial magnetic stimulation brain connectivity changes in major depression visible on MRI scan
by Rod Tucker
3
Amino acids supplement reduces muscle wasting and improves gut function in critically ill
by Rod Tucker
4
Less than two-thirds of patients alive 10 years after out-of-hospital cardiac arrest
by Rod Tucker
5
Launch of the new Hospital Pharmacy Europe Mobile App
by aporter2
Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe
x
Search for: